[HTML][HTML] In-silico prediction of synergistic anti-cancer drug combinations using multi-omics data
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
3In-silico prediction of synergistic anti-cancer drug combinations using multi-omics data
R Çelebi, OBD Walk, R Movva, S Alpsoy, M Dumontier - 2019 - openaccess.tau.edu.tr
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
R Celebi, OB Don't Walk, R Movva, S Alpsoy… - Scientific Reports, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Chemotherapy is a routine treatment approach
for early-stage cancers, but the effectiveness of such treatments is often limited by drug …
for early-stage cancers, but the effectiveness of such treatments is often limited by drug …
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
R Celebi, O Bear Don't Walk, R Movva… - Scientific …, 2019 - ui.adsabs.harvard.edu
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
R Celebi, OB Don't Walk, R Movva… - Scientific …, 2019 - cris.maastrichtuniversity.nl
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
[HTML][HTML] In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
R Celebi, R Movva, S Alpsoy, M Dumontier - Scientific Reports, 2019 - ncbi.nlm.nih.gov
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data.
R Celebi, O Bear Don't Walk, R Movva, S Alpsoy… - Scientific …, 2019 - europepmc.org
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
R Celebi, OB Don't Walk 4th, R Movva… - Scientific …, 2019 - pubmed.ncbi.nlm.nih.gov
Chemotherapy is a routine treatment approach for early-stage cancers, but the effectiveness
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …
of such treatments is often limited by drug resistance, toxicity, and tumor heterogeneity …